Ciglitazone is a PPARγ agonist. It decreases insulin levels, VEGF production, and blood pressure and induces cell cycle arrest in stomach cancer cells.
Ciglitazone is a PPARγ agonist. It decreases insulin levels, VEGF production, and blood pressure and induces cell cycle arrest in stomach cancer cells.